Salute e Benessere

Near infrared Imaging Market worth US$2.07 billion by 2030 with 10.6% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174869738 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174869738 Browse in-depth TOC on "Near infrared Imaging Market" 421 - Tables64 - Figures408 - Pages By product,the device segment is expected to dominate the market during the forecast period. The device segment comprises fluorescence imaging systems and fluorescence & bioluminescence imaging...
PR Newswire
30/08/2025

Roche and Alnylam advance zilebesiran into global phase III cardiovascular…

Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3In the Phase II KARDIA-3 study, presented today as a late breaker at the European Society of Cardiology Congress 2025, zilebesiran demonstrated clinically meaningful reductions in office systolic blood pressure at month three with continuous control through month sixZilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly...
Nasdaq GlobeNewswire
30/08/2025

Ultrasound AI Market worth $6.88 billion by 2030 with 24.0% CAGR |…

Browse in-depth TOC on "Ultrasound AI Market" Browse in-depth TOC on "Ultrasound AI Market" 389 - Tables45 - Figures278 - Pages By product type,the market is segmented by product type into AI-enabled ultrasound systems and AI-enabled solutions/software. The AI-enabled solutions/software are segmented into image evaluation software, radiology software, workflow planning & support software, and other AI solutions. The AI-enabled solutions/software segment is expected...
PR Newswire
30/08/2025

Oral Rinses Market worth US$5.89 billion by 2030 with 6.5% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171496243 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171496243 Browse in-depth TOC on "Oral Rinses Market" 210 - Tables 60 - Figures 237 - Pages By product type,Therapeutic mouth rinses constitute the predominant segment of the oral care market, primarily due to their efficacy in both the prevention and management of oral pathologies, underpinned by...
PR Newswire
30/08/2025

US FDA approves Leqembi® IQKLIK™ (lecanemab-irmb) subcutaneous injection for…

Alzheimer's disease is a progressive, relentless disease with Aβ and tau as hallmarks. It progresses in stages that increase in severity over time, and each stage of the disease presents different challenges for those living with the disease and their care partners. There is a significant unmet need for new treatment options that slow the progression of Alzheimer's disease from its early stage and reduce the overall burden on people affected by Alzheimer's disease and society. Only Leqembi…
PR Newswire
30/08/2025

Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune…

Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other ITP symptomsITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life; more than 25,000 US adults could benefit from advanced...
Nasdaq GlobeNewswire
29/08/2025

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for…

LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless diseaseafter initial treatment of 18 monthsLEQEMBI IQLIK will be launched on October 6, 2025, in the U.S. TOKYO and CAMBRIDGE, Mass., Aug.29, 2025(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO:...
Nasdaq GlobeNewswire
29/08/2025

Information on the total number of voting rights and shares

REGULATED INFORMATIONInformation on the total number of voting rights and sharesMont-Saint-Guibert(Belgium), August 29, 2025 , 10:30 pm CET / 4:30 pm ET –In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6,449,871.98 Total number of securities carrying voting rights: 37,544,782 (all ordinary...
Nasdaq GlobeNewswire
29/08/2025

Smile Hair Clinic Becomes the First Hair Transplant Clinic in the World to…

Based in Germany, TEMOS operates in more than 20 countries and is known for its strict evaluations of hospitals and healthcare institutions. These inspections cover not only medical quality, but also patient and staff safety, ethical practices, sustainability, quality management, infrastructure, and service security. Based in Germany, TEMOS operates in more than 20 countries and is known for its strict evaluations of hospitals and healthcare institutions. These inspections cover not only...
PR Newswire
29/08/2025

Innocan Pharma Announces Details of Proposed Share Consolidation

Innocan has applied to list its Common Shares and Warrants on the Nasdaq Capital Market under the symbols "INNP" and "INNPW", respectively. Innocan has applied to list its Common Shares and Warrants on the Nasdaq Capital Market under the symbols "INNP" and "INNPW", respectively. ThinkEquity LLC is acting as representative underwriter in the offering. This proposed offering will be made only by means of a prospectus. Upon availability, copies of the…
PR Newswire
29/08/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from August 18 thto August 22 nd2025Name of the issuerIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1118/08/2025FR0010259150 600113...
Nasdaq GlobeNewswire
29/08/2025

Portable Ultrasound Market worth US$3.84 billion by 2030 with 9.0% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=114058057 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=114058057 Browse in-depth TOC on "Portable Ultrasound Market" 384 - Tables 45 - Figures 245 - Pages By product type,Transducers/probes are experiencing the highest CAGR in the portable ultrasound market because they are critical components that directly impact image quality and diagnostic accuracy,...
PR Newswire
29/08/2025

Pharmaceutical Contract Manufacturing Market worth US$311.95 billion by 2030…

Browse in-depth TOC on "Pharmaceutical Contract Manufacturing Market" Browse in-depth TOC on "Pharmaceutical Contract Manufacturing Market" 450 - Tables60 - Figures456 - Pages By service,the global pharmaceutical contract manufacturing market is segmented by service into drug development services, pharmaceutical manufacturing services, biologic manufacturing services, packaging & labelling services, fill-finish services, and other services. In 2024, the...
PR Newswire
29/08/2025

Embla Medical hf: Embla Medical closes the majority share investment in…

Reference is made to announcement no. 31/2025 published on 17 July 2025 (Embla Medical signs agreement to invest in a majority share in Streifeneder ortho.production GmbH). Reference is made to announcement no. 31/2025 published on17 July 2025(Embla Medical signs agreement to invest in a majority share in Streifeneder ortho.production GmbH). REYKJAVIK, Iceland and COPENHAGEN, Denmark, Aug. 29, 2025 /PRNewswire/ -- Embla Medical (NASDAQ Copenhagen: EMBLA), a leading global...
PR Newswire
29/08/2025

Seminar: IP That Matters - Behind Orexo's Milestone Patent Win at the US Court

Orexo has successfully developed four drugs from concept to market, including Zubsolv® for opioid dependence, which is commercialized by Orexo in the US. The company has extensive experience in building robust patent strategies that support product development cycles. Orexo has demonstrably and repeatedly benefited from these strategies, including when its innovations have been challenged by leading international generic companies, such as Actavis/Teva in 2018 and, more recently, Sun…
PR Newswire
29/08/2025

Morphy Richards Brings "Innovate for Enlightening Progress" to IFA Berlin 2025

Building on the success of the S1 Pro—the world's first ductless air conditioner, which raised about $1 million on Kickstarter and earned accolades at IFA 2024, Morphy Richards will debut the S1 Ultra at IFA 2025. Powered by Fusion Max Tech, the S1 Ultra offers five-in-one functionality, including cooling, heating, humidifying, airflow, and ductless operation, providing year-round comfort. Inspired by aircraft engines and accented with subtle wood elements, it combines advanced innovation with…
PR Newswire
29/08/2025

Vaccine Refrigerators Market Size to Reach US$ 2.50 Billion by 2033 with 7.6%…

In parallel, manufacturers such as Haier Biomedical, B Medical Systems, and Thermo Fisher Scientific Inc. are innovating with IoT-enabled monitoring, green refrigerants, and energy-efficient models, aligning with global sustainability goals while reducing vaccine wastage. As governments, NGOs, and private healthcare providers continue to strengthen cold chain systems, the market is expected to expand toward smarter, greener, and more resilient refrigeration solutions, ensuring that vaccines…
PR Newswire
29/08/2025

Gateway to Growth: Innovation and Opportunity at the 8th CIIE

At the supply-demand matchmaking event of the 8th CIIE, companies showcased 22 "CIIE Babies" —products that have successfully entered the market after their debut at previous expos, including two making their first post-launch appearance, underscoring the CIIE's role in turning exhibits into goods. Medical innovations have also gained ground in China. Novartis built on its RLT debut last year by partnering with GE Healthcare China and others to create an RLT ecosystem. Meanwhile…
PR Newswire
29/08/2025

Purepeak: Korean Anti-Aging Brand Chosen by European Pharmacies

Purepeak's signature "Beauty Solid Line" features concentrated, plant-derived ingredients in a solid stick formula that delivers hydration, nourishment, and anti-aging benefits in one. Infused with botanical extracts for deep skin nutrition and UV-blocking ingredients to protect against photoaging, the line goes beyond basic sun protection—positioning itself as part of a comprehensive anti-aging routine. This innovative approach aligns with the growing "skinimalism" trend…
PR Newswire
29/08/2025

New number of shares and votes in Sobi

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with...
PR Newswire
29/08/2025

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes…

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM Nantes, August 29, 2025, 8:00 a.m. CET -OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today published a comprehensive Questions and Answers document in advance of its Annual General Meeting (AGM) convened on September 30, 2025. The document provides clear, factual information about financing, governance, scientific development and the...
Nasdaq GlobeNewswire
29/08/2025

UCB presents latest research and clinical advancement across leading epilepsy…

Highlights of data to be presented at IEC: Highlights of data to be presented at IEC: Fenfluramine: A combined open-label extension (OLE) study enrolled 412 patients with DS or LGS who had participated in three previous fenfluramine studies, reporting no new or unexpected safety signals and long-term sustained benefit. [2] Barriers and benefits of identifying patients with DEEs in adult care settings: Although the diagnosis of DEEs in children has become routine,...
PR Newswire
29/08/2025

PCI Biotech half-year interim 2025 report

Highlights review OperationsPCI Biotech decided on 18th August 2025 to discontinue further development of the PCL technology. The decision was primarily based on, as described in a press release the same day, insufficient progress towards the 2025 goal of demonstrating improved net yield at mini benchtop bioreactor scale. Achieving successful results at this scale was a critical risk-reducing milestone for further development. Following the progress reported in the preliminary 2024...
Nasdaq GlobeNewswire
29/08/2025

Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of…

Pratteln, Switzerland , 29 August , 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE® (vamorolone) in India, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. The agreement between Santhera and Ikris has a 5-year term and Santhera will receive a percentage of net sales, in line with previous distribution agreements. Sales are...
Nasdaq GlobeNewswire
29/08/2025
Altri  Comunicati